Users online: 2952    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2016, Volume : 9, Issue : 10
First page : ( 1782) Last page : ( 1785)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2016.00360.7

Non-alcoholic fatty liver disease

Choudhari Sahil1,*, Jothipriya Mrs. A.2

1I BDS, Department of Physiology, Saveetha Dental College, Chennai-600 077

2Lecturer, Department of Physiology, Saveetha Dental College, Chennai-600 077

*Corresponding Author E-mail: choudharisahil@gmail.com,

Online published on 2 March, 2017.


Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition affecting adults and children, leading to significant morbidity. It is often associated with the metabolic syndrome, although multiple pathogenetic mechanisms have been suggested. In the coming decades, it promises to be the leading cause of liver disease in industrial countries. Clinic opathologically, it represents a wide spectrum of histologic abnormalities and clinical outcomes, ranging from benign hepatic steatosis to cirrhosis. Pathophysiologically, insulin resistance is thought to be pivotal in the development of steatosis, after which a second oxidative stressor produces lipid peroxidation and nonalcoholic steatohepatitis (NASH). Liver biopsy is the gold standard for diagnosis and prognosis. The need for an effective treatment is both clear and urgent, yet in the absence of proven therapies, treatment is directed toward weight loss and comorbidity management.



Cirrhosis, Liver Biopsy, Non-alcoholic Steatohepatitis.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
446,243,275 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.